Eledon Pharmaceuticals Announces Recent Business Highlights and Third Quarter 2024 Financial Results
Provided By GlobeNewswire
Last update: Nov 12, 2024
Completed enrollment of Phase 2 BESTOW trial of tegoprubart in kidney transplantation four months ahead of schedule; on track to report topline results in fourth quarter of 2025
Read more at globenewswire.com4.32
-0.03 (-0.69%)
Find more stocks in the Stock Screener
ELDN Latest News and Analysis
